Aldeyra (ALDX) said its dry eye drug reproxalap had demonstrated broad-based, rapid-onset activity, consistent safety, and statistically significant, clinically relevant activity across Phase 2 and Phase 3 trials. Investors were told reproxalap had shown broad-based, rapid-onset activity, consistent safety, and statistically significant, clinically relevant activity across multiple trials. But the lawsuit says those trial results were actually inconsistent, making the positive findings unreliable.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
A securities lawsuit filed against Aldeyra Therapeutics alleges the company misled investors about the reliability of clinical trial data for its lead drug candidate, reproxalap, before the FDA issued a Complete Response Letter for the application, and the stock fell more than 70% in a single session.
Investors who purchased Aldeyra Therapeutics (NASDAQ: ALDX) shares between November 3, 2023, and March 16, 2026, may have suffered losses tied to what plaintiffs allege were materially false statements about the strength and consistency of reproxalap’s clinical trial results. The complaint was filed on March 30, 2026, in the United States District Court for the District of Massachusetts.
If you purchased ALDX shares during the class period and wish to learn more about your potential eligibility, consider consulting with a securities attorney.
Aldeyra Therapeutics: A Biotech Built Around a Novel Drug Platform
Aldeyra Therapeutics is a Delaware-incorporated biotechnology company headquartered in Lexington, Massachusetts, focused on developing therapies for immune-mediated diseases. The company’s shares trade on the NASDAQ under the ticker symbol ALDX. Central to its pipeline is reproxalap, a first-in-class reactive aldehyde species (RASP) inhibitor being investigated primarily as a treatment for dry eye disease. The company’s stated mission, as described in the complaint, is to discover innovative therapies designed to treat immune-mediated conditions.
What the Lawsuit Claims About Reproxalap’s Trial Data
The lawsuit centers on allegations that Aldeyra repeatedly told investors its reproxalap clinical trials demonstrated consistent, statistically significant, and clinically relevant results, when in reality the trial data were allegedly inconsistent and unreliable. Plaintiffs argue that the company’s statements across multiple years of SEC filings portrayed the RASP platform as validated by the drug’s performance across Phase 2 and Phase 3 trials, without disclosing that the inconsistency of those results undermined any positive findings. The overarching allegation is that investors were not told the trial results were allegedly inconsistent and that this inconsistency rendered the positive findings unreliable, a concern the FDA later echoed in the Complete Response Letter.
To follow developments in this case as they unfold, consider monitoring legal and regulatory filings related to ALDX.
Statements Management Made During the Alleged Misconduct Period
According to the complaint, Aldeyra’s leadership signed and filed multiple reports with the SEC that contained representations regarding reproxalap’s clinical performance. The 2023 third-quarter report stated that reproxalap had demonstrated broad-based, rapid-onset activity and consistent safety across Phase 2 and Phase 3 trials. The company’s annual reports for fiscal years 2023, 2024, and 2025 repeated similar language, stating that the drug demonstrated consistent statistically significant and clinically relevant activity across a variety of symptoms and signs, occurring as early as within minutes of dosing. CEO Todd C. Brady signed all four filings; CFO Bruce M. Greenberg signed the earlier ones, and Michael Alferi signed the later reports.
How the Alleged Truth Came to Light
On March 17, 2026, before the market opened, Aldeyra filed a Form 8-K disclosing receipt of a Complete Response Letter from the FDA. The FDA’s letter stated that the application failed to demonstrate efficacy in adequate and well-controlled studies and that inconsistencies in study results raise serious concerns about the reliability and meaningfulness of the positive findings. Following this disclosure, Aldeyra’s stock price fell $2.99 per share, a decline of approximately 70.7%, closing at $1.24 on March 17, 2026.
What This Means for Investors Who Held ALDX
The lawsuit alleges that investors who purchased Aldeyra shares during the class period did so at prices artificially inflated by management’s allegedly misleading statements about the drug’s clinical data. When the FDA’s Complete Response Letter disclosed that the application failed to demonstrate efficacy and cited inconsistent study results, the stock collapsed. The case raises questions about how companies in clinical-stage drug development communicate the strength and consistency of trial data to the investing public.
The Legal Framework Underlying the Claims
The complaint asserts violations of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, alleging that defendants made untrue statements of material fact and omitted information necessary to make their statements not misleading. Section 20(a) claims are also brought against the individual defendants as controlling persons of Aldeyra who are alleged to have directed or participated in the conduct at issue.
If you purchased ALDX shares during the class period and wish to understand your legal rights, you may want to speak with a qualified securities attorney.
About Levi & Korsinsky, LLP
Levi & Korsinsky, LLP is a nationally recognized securities litigation firm representing investors in complex shareholder actions. The firm has extensive expertise and a team of over 70 employees to serve our clients. Attorney advertising. Prior results do not guarantee similar outcomes.
Disclaimer: This article is provided for informational purposes only and does not constitute legal advice. No attorney-client relationship is created by reading this article. Past results do not guarantee similar outcomes.